Related Experiment Video
Updated: Jun 25, 2026
07:24
Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid
Published on: May 25, 2022
Genetically engineered Newcastle disease virus for malignant melanoma therapy
1Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA. dmitriy.zamarin@mssm.edu
Gene Therapy
|February 27, 2009
Summary
A novel oncolytic Newcastle disease virus (NDV) engineered to express interleukin-2 (IL-2) demonstrates potent anti-melanoma activity. This enhanced NDV effectively clears tumors and improves survival in preclinical models, offering a promising new cancer therapy.
Area of Science:
- Oncology
- Virology
- Immunotherapy
Background:
- Malignant melanoma remains a therapeutic challenge due to poor response to conventional chemotherapy.
- Current systemic therapies like interferon and interleukin-2 (IL-2) have limitations including significant side effects.
- Oncolytic viruses, specifically Newcastle disease virus (NDV), are being explored as alternative cancer treatments.
Purpose of the Study:
- To investigate the efficacy of a recombinant NDV engineered to express IL-2 for malignant melanoma therapy.
- To evaluate the oncolytic potential and immunomodulatory effects of IL-2-expressing NDV against melanoma.
Main Methods:
- Development of a recombinant NDV expressing murine IL-2.
- Assessment of cytolytic activity against various melanoma cell lines in vitro.
- Evaluation of therapeutic efficacy in a syngeneic murine melanoma model, including tumor clearance and survival analysis.
Main Results:
- Recombinant NDV exhibited significant cytolytic effects on multiple melanoma cell lines.
- IL-2-expressing NDV demonstrated effectiveness in clearing established syngeneic melanoma tumors in mice.
- Enhanced viral therapy led to improved animal survival and induced antitumor immunity.
Conclusions:
- Recombinant IL-2-expressing NDV is a potent agent against malignant melanoma in preclinical studies.
- The enhanced oncolytic and immunomodulatory properties warrant further investigation for human melanoma treatment.
